Toronto, Ontario — SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF),

a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced the following management changes. On the recommendation of President and CEO Andrew Morris, SQI’s Board of Directors has approved the promotion of Ms. Patricia Lie to Vice President Finance and Administration replacing Lennie Ryer who has left the Company as Chief Financial Officer, effective February 15, 2016.

“The extensive experience Patricia has built during her career and over her five years at SQI is well-aligned with our financial and commercialization objectives”, said Andrew Morris, CEO of SQI Diagnostics. “Patricia’s contributions as an integral member of the SQI management team will continue to be very valuable as we transition to profitability and our financial profile changes accordingly”

Ms. Lie brings over 20 years of financial and strategic management experience and for the past five years Ms. Lie has held the position of Director of Finance and Administration at SQI. Prior to joining SQI, Ms. Lie was Professor of Business (Accounting) at Sheridan College; held various roles at Toronto Dominion Bank Financial Group following five years at PwC LLP, a Canadian public audit firm.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.